Supriya Lifescience Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Supriya Lifescience (NSE: SUPRIYA) is set to announce its Q4 FY26 financial results for the quarter and full year ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited financial statements and consider a recommendation for a final dividend for FY26. Investors tracking the Supriya Lifescience Q4 results 2026 date, earnings estimates, and analyst outlook will find all the key details in this article.

With Supriya Lifescience trading at a current market price of Rs 248 against a 52-week high of Rs 420 and a 52-week low of Rs 188, the Q4 FY26 results will be a pivotal data point for investors. Analyst estimates for Q4 FY26 revenue stand at Rs 160 to 178 Cr, with PAT expectations of Rs 30 to 38 Cr and margin projections of 20 to 23%. Get free investment predictions and live Q4 result alerts on Univest.

This article covers the Supriya Lifescience Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.

Supriya Lifescience Q4 Results 2026 Date

Get free investment predictions on Univest.

Supriya Lifescience has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet to approve the audited consolidated financial statements for the quarter and full year ended March 31, 2026. The trading window for designated employees is closed until 48 hours after the results announcement, as per SEBI regulations.

Company	Q4 FY26 Results Date
TCS	April 9, 2026 (Declared)
Supriya Lifescience	May 2026 (Expected)

Source: BSE/NSE exchange filings, April 2026. Expected dates may change. Verify before relying.

Why This Quarter Matters for Supriya Lifescience

Supriya Lifescience enters Q4 FY26 with expectations of meaningful year-on-year improvement in its core Pharma API Antihistamines business. Q4 is typically a seasonally important quarter as companies execute on year-end targets, government orders pick up, and annual dividend recommendations are made. For Supriya Lifescience specifically, Q4 FY26 matters because it sets the baseline for FY27 estimates and determines full-year FY26 performance.

Every quarterly result tells a story, but Supriya Lifescience’s Q4 FY26 print will be watched closely because it sets the baseline for FY27 estimates, determines full-year FY26 performance, and provides the first clear read on whether business momentum is accelerating or decelerating. Management guidance on margins, volumes, and capital allocation will be just as important as the headline PAT number. Screen Supriya Lifescience fundamentals on the Univest Screener.

Supriya Lifescience Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Brokerages including MOFSL, YES Securities, JM Financial, and others have published their Q4 FY26 preview estimates for Supriya Lifescience. The consensus expects Rs 160 to 178 Cr in revenue for Q4 FY26, compared to Rs 148 Cr in Q3 FY26. Profit after tax (PAT) is estimated at Rs 30 to 38 Cr, with margin expectations of 20 to 23%.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate	YoY Trend
Revenue	Rs 148 Cr	Rs 160 to 178 Cr	Sequential growth expected
PAT (Net Profit)	Rs 28 Cr	Rs 30 to 38 Cr	Improvement anticipated
EBITDA Margin	18.9%	20 to 23%	Stable to marginal improvement
Revenue Growth Driver	Core business execution	Seasonal uptick plus order execution	Positive
Dividend Expectation	As per FY26 policy	Final dividend possible	Board discretion

Supriya Lifescience enters Q4 FY26 with expectations of Rs 160 to 178 Cr in revenue driven by execution on existing orders and seasonal demand pickup. Management commentary on the pipeline and deal wins will set the direction for FY27 estimates. Screen Supriya Lifescience fundamentals on the Univest Screener.

5 Key Factors That Will Drive Supriya Lifescience Q4 FY26 Performance

1. Revenue Execution and Order Book Conversion

Supriya Lifescience enters Q4 FY26 with a focus on executing on its existing order book and converting pipeline into recognised revenue. Q4 is seasonally important for the Pharma API Antihistamines sector and the ability to deliver on committed orders will be the first performance test. Analysts expect Rs 160 to 178 Cr in revenue for Q4 FY26. A beat here would signal improving execution capability and set a strong base for FY27 guidance. Track live revenue updates on the Univest Screener.

2. Margin Recovery and Cost Control

Q4 FY26 margin expectations are 20 to 23% versus 18.9% in Q3 FY26. Input cost trends, employee expense efficiency, and pricing power in key markets will collectively determine whether Supriya Lifescience can sustain or improve on Q3 margins. Any margin beat here would be a meaningful positive catalyst for the stock and for FY27 earnings visibility.

3. Final Dividend and Capital Allocation Signals

Q4 board meetings are typically when companies announce their final dividend for the fiscal year. Supriya Lifescience’s capital allocation stance, including whether it maintains, increases, or skips the final dividend, will signal management confidence in the business outlook. A higher-than-expected dividend payout would be a positive surprise for income-focused investors tracking the Supriya Lifescience Q4 results 2026.

4. FY27 Management Guidance

Investors should monitor revenue versus Rs 160 to 178 Cr and PAT versus Rs 30 to 38 Cr as the two primary watchpoints. If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter in the current environment. Get SEBI-registered research on Univest.

5. Sector Tailwinds and Macro Environment

The Pharma API Antihistamines sector in India is benefiting from structural demand drivers including government capex, domestic consumption recovery, and a supportive policy environment. Supriya Lifescience’s ability to translate these sector tailwinds into quarterly earnings growth will be closely watched by institutional investors. The RBI rate cut cycle that commenced in 2026 has also reduced borrowing costs across the sector, providing a further boost to profitability.

5 Risks to Watch in Supriya Lifescience Q4 FY26

1. Revenue Miss Risk

If revenue comes in below the Rs 160 to 178 Cr estimate range, it would signal execution challenges in the Pharma API Antihistamines business. A miss at the revenue line typically triggers a cascading impact on PAT and margin, amplifying the negative reaction in the stock price.

2. FII Selling Pressure

FIIs sold Rs 22,000 crore in Indian equities in a single week following the US tariff announcement in early April 2026. Continued selling would create headwinds for Supriya Lifescience regardless of company-specific fundamentals. With global risk appetite still cautious, institutional positioning remains a key external risk for the stock heading into Q4 results.

3. Margin Compression Risk

Input cost inflation, wage increases, and pricing pressure in key markets could compress Supriya Lifescience’s margins below the 20 to 23% estimate. Any margin miss combined with a revenue miss creates a double negative that typically leads to sharp post-results corrections. Monitor margin trends on the Univest Screener.

4. Regulatory and Policy Risks

The Pharma API Antihistamines sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect Supriya Lifescience’s profitability beyond current consensus models. Any negative regulatory development announced alongside the Q4 results could weigh on investor sentiment.

5. Weak FY27 Guidance Risk

Even if Q4 FY26 numbers come in line with estimates, a below-consensus FY27 guidance from management would be the single biggest negative catalyst. The market prices stocks on forward earnings, and a guidance cut would compress the valuation multiple applied to Supriya Lifescience’s earnings, pushing the stock lower despite an acceptable reported quarter.

Supriya Lifescience Share Price and Analyst Ratings

Supriya Lifescience is trading at Rs 248 as of April 2026, against a 52-week high of Rs 420 and 52-week low of Rs 188. The stock has a market capitalisation of approximately Rs 1280 Cr. Download the Univest iOS App or Univest Android App for live Supriya Lifescience Q4 result alerts and SEBI-registered research.

Brokerage	Rating	Target Price	Key Thesis
MOFSL	Buy	Rs 320	Supriya Lifescience Pharma API Antihistamines sector growth outlook FY27
YES Securities	Buy	Rs 312	Supriya Lifescience Pharma API Antihistamines sector growth outlook FY27
Emkay	Neutral	Rs 295	Supriya Lifescience Pharma API Antihistamines sector growth outlook FY27

Conclusion

Supriya Lifescience Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma API Antihistamines sector. Analysts project PAT of Rs 30 to 38 Cr and revenue of Rs 160 to 178 Cr. FY27 guidance will be the most critical post-results catalyst alongside the headline Q4 numbers. For more Q4 FY26 previews, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Frequently Asked Questions

What is the Supriya Lifescience Q4 results 2026 date?

The Supriya Lifescience Q4 results 2026 date is May 2026 (Expected). The board of directors will meet on this date to approve the audited financial results for the quarter and full year ended March 31, 2026.

What is the Supriya Lifescience Q4 FY26 PAT estimate?

Analyst consensus estimates Supriya Lifescience Q4 FY26 PAT at Rs 30 to 38 Cr, based on revenue of Rs 160 to 178 Cr and margin of 20 to 23%. The actual number will be declared on May 2026 (Expected).

What is Supriya Lifescience’s share price ahead of Q4 results?

Supriya Lifescience is trading at Rs 248 ahead of Q4 FY26 results. The 52-week high is Rs 420 and the 52-week low is Rs 188. The market cap is approximately Rs 1280 Cr. Track live price on the Univest Screener.

Will Supriya Lifescience declare a dividend in Q4 2026?

The Supriya Lifescience board may consider a final dividend for FY26 at its Q4 results board meeting on May 2026 (Expected). Dividend decisions are at board discretion and depend on the company’s profitability and cash flow position for the full year. Track dividend announcements on NSE or the Univest Screener.

Which analysts have a Buy rating on Supriya Lifescience?

MOFSL (Target: Rs 320), YES Securities (Target: Rs 312). Analyst ratings and target prices change frequently. Always verify the latest ratings on the Univest Screener.

What were Supriya Lifescience Q3 FY26 results?

Supriya Lifescience reported revenue of Rs 148 Cr and PAT of Rs 28 Cr in Q3 FY26, with an operating margin of 18.9%. The Q4 FY26 results on May 2026 (Expected) will provide the next quarterly update. Get detailed financial analysis on Univest.

When does TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Find the full TCS Q4 FY26 analysis on Univest Blogs.

Is Supriya Lifescience a good investment ahead of Q4 results?

Whether Supriya Lifescience is a good investment ahead of Q4 FY26 results depends on your investment horizon and risk appetite. At Rs 248, the stock is trading at a discount to its 52-week high of Rs 420. Analyst consensus targets range from Rs 295 to Rs 320. Always consult a SEBI-registered financial advisor before making any investment decision. Get free research on Univest.

Recent Article

VRL Logistics Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Vraj Iron and Steel Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Voltas Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Voltamp Transformers Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Vodafone Idea Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook